IQVIA Holdings Inc. with ticker code (IQV) now have 18 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $295.00 and $235.00 with the average target price sitting at $271.17. Given that the stocks previous close was at $219.23 this would imply there is now a potential upside of 23.7%. It’s also worth noting that there is a 50 day moving average of $230.70 while the 200 day moving average is $221.16. The market cap for the company is 39.32B. The stock price for the company is currently $215.83 USD
The potential market cap would be $48,640,926,144 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 29.48, revenue per share of $82.42 and a 5.03% return on assets.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
